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Yunching Chen1, Surendar R. Bathula1, Qi Yang1 and Leaf Huang1
Melanoma is a severe skin cancer that often leads to death. To examine the potential of small interfering RNA
(siRNA) therapy for melanoma, we have developed anisamide-targeted nanoparticles that can systemically
deliver siRNA into the cytoplasm of B16F10 murine melanoma cells, which express the sigma receptor. A c-Myc
siRNA delivered by the targeted nanoparticles effectively suppressed c-Myc expression in the tumor and
partially inhibited tumor growth. More significant tumor growth inhibition was observed with nanoparticles
composed of N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammonium chloride (DSAA), a guanidinium-
containing cationic lipid, than with a commonly used cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP). Three daily injections of c-Myc siRNA formulated in the targeted nanoparticles containing DSAA
could impair tumor growth, and the ED50 of c-Myc siRNA was about 0.55mgkg
1. The targeted DSAA
nanoparticles containing c-Myc siRNA sensitized B16F10 cells to paclitaxel (Taxol), resulting in a complete
inhibition of tumor growth for 1 week. Treatments of c-Myc siRNA in the targeted nanoparticles containing
DSAA also showed significant inhibition on the growth of MDA-MB-435 tumor. The enhanced anti-melanoma
activity is probably related to the fact that DSAA, but not DOTAP, induced reactive oxygen species, triggered
apoptosis, and downregulated antiapoptotic protein Bcl-2 in B16F10 melanoma cells. Thus, the targeted
nanoparticles containing c-Myc siRNA may serve as an effective therapeutic agent for melanoma.
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INTRODUCTION
Melanoma is the most serious type of skin cancer in the
world, accounting for about 80% of deaths. Most patients
develop metastases with the 5-year survival rate being only
14% (Sulaimon and Kitchell, 2003). Currently, improved
therapeutic options such as chemotherapy and immunother-
apy are increasing but the therapeutic outcome is still limited
because of the resistance of melanoma cells to these agents
(Atallah and Flaherty, 2005; Hersey, 2006; Zhang et al.,
2006). Most therapeutic agents trigger anticancer effects by
induction of apoptosis or generation of reactive oxygen
species (ROS; Hersey, 2006; Tuma, 2008). However, the best
response rate produced by a single-agent chemotherapy or
biochemotherapy for melanoma is only 16% (Atallah and
Flaherty, 2005; Tas et al., 2005). There is still ample room for
improvement in the treatment strategy (Mathieu et al., 2007).
Overexpression of c-Myc has been found in more than half
of human cancers (Nesbit et al., 1999). More than 2,000
MYC-responsive genes have been identified. They are
involved in cell cycle control, proliferation, cell death, cell
adhesion, biosynthesis of ribosomal and transfer RNAs,
protein synthesis, and metabolism (Dang et al., 2006). In
melanoma, c-Myc expression is essential for nucleotide
metabolism and proliferation of tumor cells (Mannava
et al., 2008). Overexpression of c-Myc during progression
of melanoma continuously suppresses oncogene-induced
senescence in the cells (Zhuang et al., 2008). In this study,
we explored the possibility of small interfering RNA (siRNA)
against c-Myc as a therapy for subcutaneous malignant
melanoma in a syngeneic murine model and human
xenograft tumor models (Hong et al., 2006; Li et al., 2008b).
siRNA therapy is a novel but potentially effective strategy
for cancer treatment, with reduced toxicity compared with
that commonly found with conventional cytotoxic drugs
(Devi, 2006). Combination therapy using siRNA and one or
more chemotherapy drugs may be beneficial in decreasing
the required dose of the drug and improving the therapeutic
effect. Downregulation of the epithelial growth factor
receptor sensitizes small cell lung carcinoma to cisplatin,
resulting in a significantly improved growth inhibition
(Li et al., 2008a). siRNA against SLUG, which is required
for melanoma cell survival and metastasis progression,
enhances the efficacy of cisplatin and fotemustine (Vannini
et al., 2007). SiRNA-based therapy was also developed to
treat melanoma (Amarzguioui et al., 2006; Liu et al., 2009;
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Villares et al., 2008; Zamora-Avila et al., 2009). For example,
a combination of siRNAs against MDM2, c-Myc, and VEGF
showed a tumor growth inhibition effect in the B16F10
melanoma lung metastasis model (Li et al., 2008b). Systemic
delivery of protease-activated receptor-1 siRNA significantly
inhibited melanoma growth and metastasis (Villares et al.,
2008). Furthermore, STAT3 siRNA delivered with a lipid-
substituted polyethylenimine induced apoptosis in B16
melanoma (Alshamsan et al., 2010).
To increase the stability of siRNA in the blood and
promote selective uptake of siRNA into the tumor cells, we
have developed targeted liposome-polycation-DNA (LPD)
nanoparticles containing cationic liposomes that are efficient
at delivering siRNA to several different solid tumors in mouse
models (Li et al., 2008a, b). Here we show that a nanoparticle
formulation targeted with anisamide, which binds with the
sigma 1 receptor of melanoma cells, is effective in delivering
siRNA to B16F10 melanoma in a murine syngeneic model.
Furthermore, a cationic lipid N,N-distearyl-N-methyl-N-2-
(N0-arginyl) aminoethyl ammonium chloride (DSAA), which
contains an arginine residue as the head group, was
particularly suitable as a formulation lipid. Our study
indicates that c-Myc siRNA, delivered by DSAA-containing
nanoparticles, may affect different signaling pathways and
sensitize the melanoma cells to chemotherapeutic agents
such as paclitaxel. The nanoparticle formulation showed
minimal immunotoxicity in normal mice.
RESULTS
Intracellular uptake of siRNA in B16F10 melanoma cells
We used anisamide-targeted LPD nanoparticles containing
DSAA as a carrier lipid to specifically deliver siRNA to
cultured B16F10 melanoma cells, which express the sigma
receptor. The structure of DSAA is shown in Figure 1. The
size of the nanoparticles was about 100 nm and the
z potential was about 25mV. To characterize the formula-
tion, we used FITC-labeled siRNA to prepare targeted
nanoparticles using DSAA as the cationic lipid. The final
formulation was fractionated by Sepharose CL 2B column
chromatography. Supplementary Figure S1 online indicates
that the amount of siRNA loaded into the final formulation
was about 85% of the total siRNA. Because DSAA has not
previously been reported, we compared the data collected
with nanoparticles containing DSAA and with those
containing a previously used lipid, 1,2-dioleoyl-3-trimethy-
lammonium-propane (DOTAP). Table 1 summarizes the
abbreviations used for the different formulations. As shown
in Figure 2a, confocal microscopy showed that nanoparticles
containing DSAA could deliver Cy-3-labeled siRNA into the
cytoplasm of B16F10 cells more efficiently than those
containing DOTAP. Furthermore, Cy-3 siRNA uptake by the
cells treated with the targeted nanoparticles DSAA AAþ was
much more efficient than that by cells treated with the
nontargeted nanoparticles DSAA AA. The results indicate
that the nanoparticles containing DSAA could efficiently
deliver siRNA into the tumor cells and the delivery was
significantly enhanced by the presence of the targeting ligand
(AA) on the nanoparticles.
Luciferase gene silencing in vitro
B16F10 cells stably transduced with the firefly luciferase gene
were used to study in vitro gene silencing. The luciferase
gene silencing effect of the nanoparticles containing DSAA
was stronger than that of those containing DOTAP (Figure 2b).
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Figure 1. Chemical structures of DSAA and DOTAP. Chemical structures of DSAA (a) and DOTAP (b). DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane;
DSAA, N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammonium chloride.
Table 1. Abbreviations for the formulations used in
the study
Abbreviation Explanation
LPD Liposome-polycation-DNA
DSAA AA+ LPD nanoparticles containing DSAA modified
with PEG with an anisamide ligand
DSAA AA LPD nanoparticles containing DSAA modified
with PEG without any targeting ligand
DOTAP AA+ LPD nanoparticles containing DOTAP modified
with PEG with an anisamide ligand
DOTAP AA LPD nanoparticles containing DOTAP modified
with PEG without any targeting ligand
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Furthermore, the silencing effect in the cells treated with the
targeted nanoparticles was much higher than that of cells
treated with the nontargeted nanoparticles, when DSAA was
the carrier lipid. The result correlated very well with that of
the intracellular siRNA uptake (Figure 2a).
Tissue distribution and intracellular uptake of siRNA and lipid
We further studied the siRNA and lipid distribution and
bioavailability of major tissues in the B16F10 melanoma
model in C57BL/6 mice. We used 10mol% 7-nitro-2-1,3-
benzoxadiazol cholesterol-labeled liposomes (green) and Cy-
3-labeled siRNA (red) to prepare PEGylated LPD and the final
formulation was intravenously administered into the tumor-
bearing mice. As shown in Figure 3a, a clear overlap (yellow/
orange) between NBD-cholesterol-labeled liposomes and Cy-
3-labeled siRNA was observed, indicating intact nanoparti-
cles were taken up by the tumor cells. The targeted
nanoparticles containing DSAA or DOTAP (DSAA AAþ or
DOTAP AAþ ) showed higher cytosolic delivery of Cy-3
siRNA and NBD cholesterol in the tumor tissue than the
nontargeted nanoparticles (DSAA AA or DOTAP AA).
Because the non-PEGylated liposomes containing DSAA/chol
were a crucial component of the targeted nanoparticles
(DSAA AAþ ), we compared the lipid (NBD cholesterol)
uptake of DSAA AAþ with that of the non-PEGylated
liposomes containing DSAA/chol. For quantitative results of
lipid uptake (Figure 3b), the targeted nanoparticles containing
DSAA showed higher lipid delivery in the tumor tissue than
the non-PEGylated liposomes containing DSAA, whereas
other tissues showed lower uptake of lipid when treated with
the targeted nanoparticles containing DSAA than with the
non-PEGylated liposome containing DSAA. Taken together,
these data indicated that the targeted nanoparticles contain-
ing DSAA could efficiently deliver siRNA and the carrier lipid
to the tumor tissue and the intracellular delivery was ligand
dependent.
c-Myc gene silencing in vivo
To examine the biological activities of siRNA in vivo, we
used western blotting to detect the c-Myc level in the
subcutaneous melanoma tumor (Figure 4). c-Myc in B16F10
tumor was silenced by c-Myc siRNA in the targeted
nanoparticles DSAA AAþ and DOTAP AAþ . The c-Myc
siRNA-containing DSAA AA and DOTAP AA and control
siRNA showed no effect. The results of our study indicated
that the nanoparticles containing DSAA or DOTAP could
systemically deliver siRNA into the tumor tissue and that the
delivery was specifically controlled by the targeting ligand
(AA). The result correlated well with that of the intracellular
siRNA uptake in the tumor tissue (Figure 3a).
Tumor growth inhibition
Three injections of c-Myc siRNA in DOTAP AAþ showed a
partial inhibition of tumor growth (Po0.01 at day 11) similar to
that of c-Myc siRNA in DSAA AA and control siRNA in DSAA
AAþ (Figure 5a). A significant improvement in the tumor
growth inhibition was observed with c-Myc siRNA formulated
in DSAA AAþ (Po0.0001 at day 11), with an ED50 of
0.55mgkg1 (Figure 5b). With additional treatment with
paclitaxel, which is a common first-line chemotherapy agent
for malignant melanoma, the therapeutic activity of c-Myc
siRNA formulated in DSAA AAþ showed further improvement
(Figure 5c). Tumor growth was completely inhibited by the
combination therapy for 1 week after the last dose (Figure 5c).
Because DSAA was important in the uptake and the
anticancer activity of siRNA delivered to the tumor cells, we
decided to study the biological functions of DSAA in some
detail. We first investigated the ROS activation in the B16F10
cells as it is important as an apoptosis inducer. B16F10 cells
were treated with DOTAP/chol or DSAA/chol liposomes at
different doses, and the cellular ROS content was measured
by using 20,70-dichlorodihydrofluorescein diacetate and flow
cytometry. As shown in Figure 6, DSAA could generate ROS
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Figure 2. Intracellular uptake of siRNA and luciferase gene silencing in
cultured melanoma cells. (a) Fluorescence micrographs of B16F10 cells after
treatment with 50-Cy-3-labeled siRNA in the targeted nanoparticles (AAþ ) or
the nontargeted nanoparticles (AA) containing DSAA and DOTAP. Scale
bar¼ 50 mm. (b) B16F10 cells were incubated with different formulations
containing anti-luciferase siRNA. Luciferase activity in cells was measured
after 24 hours. Each value represents the mean±SD (n¼3). DOTAP,
1,2-dioleoyl-3-trimethylammonium-propane; DSAA, N,N-distearyl-N-
methyl-N-2-(N0-arginyl) aminoethyl ammonium chloride; Luc, luciferase;
siRNA, small interfering RNA.
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in B16F10 cells more efficiently than DOTAP after 1 hour of
treatment, and the ROS induction was elevated in a dose-
dependent manner. There was a statistically significant
difference in the apoptosis induction between DSAA and
DOTAP at concentrations of 10, 25, and 50 mM after 24-hour
incubation based on flow cytometry assay using propidium
iodide and Annexin V staining (Figure 6b and c). Because it
has been reported that ROS-induced apoptosis was regulated
by the ubiquitination of Bcl-2 family proteins (Li et al., 2004),
we further studied the Bcl-2 protein expression after
treatment of DSAA or DOTAP liposomes for different time
periods in B16F10 cells. As shown in Figure 6d, 50 mM DSAA
could decrease Bcl-2 expression at 24 and 48 hours after
treatment. However, Bcl-2 expression remained unchanged
after the treatment with DOTAP. These results suggest that
ROS induced by DSAA may lead to apoptosis through Bcl-2
downregulation. Thus, silencing c-Myc by siRNA and ROS
induction and the associated Bcl-2 downregulation by DSAA
may work together to impair the growth of a melanoma tumor.
c-Myc gene silencing, apoptosis induction, and tumor growth
inhibition in human melanoma
To further evaluate the clinical potential of c-Myc siRNA
delivered by the targeted nanoparticles in human melanoma,
we investigated the apoptosis induction and growth inhibi-
tion effects using the MDA-MB-435 human melanoma cell
line (Rae et al., 2007). We first determined the biological
function of c-Myc siRNA on cell survival on MDA-MB-435
cells. Annexin V staining was carried out to detect apoptosis
72 hours after transfection. As shown in Figure 7a, apoptosis
was significantly induced after the treatment with c-Myc
siRNA compared with the control siRNA. To further evaluate
apoptosis induction by c-Myc siRNA in the MDA-MB-435
xenograft model, we examined cellular apoptosis by using
TUNEL staining (Figure 7b and c). As shown in the figure,
c-Myc in MDA-MB-435 tumor was silenced by c-Myc siRNA
in the targeted nanoparticles DSAA AAþ . Control siRNA
showed no effect. The number of TUNEL-positive cells
increased after treatments of c-Myc delivered with the
targeted nanoparticles DSAA AAþ . Intravenous injections
of control siRNA in the targeted nanoparticles DSAA AAþ
showed a slight increase in TUNEL-positive cells. Five
injections of c-Myc siRNA in the targeted nanoparticles
DSAA AAþ showed significant inhibition of tumor growth
(Po0.001 at day 10). A partial tumor growth inhibition was
observed with control siRNA formulated in DSAA AAþ
(Po0.05 at day 10; Figure 7d). These results suggested that
c-Myc siRNA triggered apoptosis in MDA-MB-435 tumor and
inhibited MDA-MB-435 melanoma growth.
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Figure 4. c-Myc expression in the tumor after treatment with siRNA in
different formulations. Mice bearing B16F10 tumors were injected
intravenously with siRNA formulated in different LPD nanoparticles.
c-Myc expression was examined by western blot analysis.
LPD, liposome-polycation-DNA; siRNA, small interfering RNA.
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Toxicity
The proinflammatory cytokine (IL-6 and IL-12) levels in the
serum were examined for evaluation of immunotoxicity
induced by our formulations in C57BL/6 mice (Supplemen-
tary Figure S2 online). c-Myc siRNA in different formulations
(DSAA AAþ , DSAA AA, DOTAP AAþ , and DOTAP AA)
induced a significant production of IL-12, whereas IL-6 was
not induced by the formulations. Empty nanoparticles
showed very mild immunotoxicity. When treated with
lipopolysaccharide (1mg kg1), both inflammatory cytokines
were induced to high levels. The data suggested that the
immunotoxicity of c-Myc siRNA in DSAA AAþ was similar
to DOTAP AAþ . Hepatotoxicity marker (aspartate amino-
transferase and alanine aminotransferase) levels in the serum
were examined for evaluation of toxicity induced by c-Myc
siRNA in the target nanoparticles DSAA AAþ in C57BL/6
mice (Supplementary Table S1 online). Aspartate amino-
transferase and alanine aminotransferase levels remained the
same as in the untreated animals. As DSAA significantly
enhanced the anticancer activity, but not the toxicity, of
c-Myc siRNA, it is a valuable formulation lipid for
nanoparticles for the delivery of siRNA against melanoma.
DISCUSSION
Previous studies showed that a mixture of siRNAs against
c-Myc, MDM2, and vascular endothelial growth factor had a
tumor-inhibition effect on the B16F10 melanoma lung
metastasis model (Li et al., 2008b). In this study, we have
improved the formulation by introducing a cationic lipid
DSAA. Anisamide-targeted LPD nanoparticles containing
DSAA effectively delivered siRNA to subcutaneous melano-
ma tumors and induced elevated apoptosis and tumor growth
inhibition. Furthermore, c-Myc siRNA so delivered also
sensitized the tumor cells to paclitaxel, a commonly used
chemotherapeutic agent for malignant melanoma.
c-Myc oncoprotein, as a general transcription factor,
regulates various key cellular processes such as cancer onset
and maintenance in human tumors. Genetic aberrations of
c-Myc promote tumorigenesis in various forms of cancer,
leading to about 70,000 cancer deaths per year in the United
States (Fest et al., 2002). In melanoma, c-Myc expression and
activation are also essential for cancer cell proliferation
(Mannava et al., 2008). Downregulation of c-Myc protein
induces apoptosis in melanoma cells and sensitizes the tumor
cells to anticancer drugs (Bucci et al., 2005; Greco et al., 2006).
It has also been shown that overexpression of MYC oncoprotein
inhibits apoptosis triggered by paclitaxel in human melanoma
(Gatti et al., 2009). Data presented in Figure 4 clearly indicate
that c-Myc oncogene in the murine melanoma model could be
effectively downregulated by using a systemic delivery vehicle
carrying siRNA against c-Myc. Such downregulation brought
tumor growth inhibition as predicted (Figure 5). The potency of
this anti-melanoma treatment, as shown by the relatively low
ED50 (0.55mgkg
1 for siRNA), compares favorably with other
siRNA-mediated therapies for cancer (Sonoke et al., 2008). The
therapy activity could be further enhanced by combining it with
a commonly used first-line chemotherapy agent, i.e., paclitaxel.
A critical element for the success of the nanoparticle
formulation is the cationic lipid DSAA. Our study data
(Figure 6d) showed that the expression of Bcl-2 was down-
regulated in B16F10 melanoma cells after the treatment with
DSAA. The reduction of Bcl-2 may be related to the induction
of ROS in B16F10 cells by DSAA (Figure 6a). Bcl-2 is an
antiapoptosis protein and overexpressed in various cancer
cells. Downregulation of Bcl-2 renders the cancer cell more
sensitive to cell death triggered by chemotherapeutic agents
or radiation and leads to inhibition of tumor growth
(Ciardiello and Tortora, 2002; Morris et al., 2005).
Chemotherapeutic drugs that promote downregulation of
Bcl-2 trigger strong apoptotic activity in B16F10 cells (Jun
et al., 2007). c-Myc and Bcl-2 cooperate to suppress p53
functions in mediating chemotherapy-induced apoptosis
(Evans et al., 2006; Ryan et al., 1994). Thus, it is not
surprising that the combination of siRNA against c-Myc and
DSAA downregulating Bcl-2 impaired the growth of the
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Figure 5. Tumor growth inhibition. (a) B16F10 tumor growth inhibition by
siRNA in different formulations. (b) Dose-dependent antitumor activity of
c-Myc siRNA formulated in DSAA AAþ . (c) The combination of c-Myc
siRNA formulated in the targeted DSAA nanoparticles and paclitaxel inhibited
B16F10 tumor growth (20mg paclitaxel per kg). Solid arrows indicate the i.v.
administrations of siRNA, and dashed-line arrows indicate the i.v. injections
of paclitaxel (N¼4–7). DSAA, N,N-distearyl-N-methyl-N-2-(N0-arginyl)
aminoethyl ammonium chloride; siRNA, small interfering RNA.
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melanoma tumor and sensitized the tumor cells to paclitaxel.
The combination therapy may also be considered for patients
who develop drug resistance in tumors with overexpressed c-
Myc. The possible mechanisms of the combination strategy
using siRNA against c-Myc and DSAA are shown in Figure 8.
DSAA induced ROS, triggered apoptosis, and downregulated
antiapoptotic protein Bcl-2, which prevents the release of
cytochrome c from mitochondria. c-Myc protein silencing by
siRNA inhibited cell proliferation and sensitized melanoma
cells to chemotherapy drugs. siRNA against c-Myc and DSAA
may cooperate to activate nuclear translocation of p53 in
mediating chemotherapy-induced apoptotic cell death in
melanoma cells.
DSAA, a guanidinium-containing cationic lipid, induced
ROS and triggered apoptosis in B16F10 melanoma cells in a
dose- and time-dependent manner (Figure 6b and c). ROS
have important functions affecting cell growth, death,
development, and survival (Thannickal and Fanburg, 2000).
Induction of ROS can initiate a lethal signal transduction
resulting in damaged cellular integrity and apoptosis (Mates
and Sanchez-Jimenez, 2000; Cejas et al., 2004; Pelicano
et al., 2004; Lebedeva et al., 2007). We suspected that the
guanidinium residue had a critical function in the induction
of ROS in the cells and that the generation of ROS
collaborated with c-Myc siRNA to inhibit tumor growth.
The activity of DOTAP in inducing ROS is very limited
(Figure 6a) and hence had no effect in enhancing the tumor
growth inhibition activity of c-Myc silencing (Figure 5a).
However, c-Myc is also involved in cell proliferation, cell
growth, differentiation, and cell death in normal cells
(Wierstra and Alves, 2008). In this study, we have used a
targeted nanoparticle formulation (DSAA AAþ ) that can
specifically deliver c-Myc siRNA into tumor tissue
(Figure 3a). Furthermore, the enhanced uptake of lipid into
the tumor also appeared to be ligand dependent. The
formulation was thus not very immunotoxic as shown in
Supplementary Figure S1 online.
In summary, c-Myc siRNA formulated in the targeted
nanoparticles containing DSAA could effectively impair
tumor growth in the B16F10 melanoma model. The formula-
tion shows great promise as an effective therapeutic agent,
perhaps used together with some traditional chemotherapies,
such as paclitaxel, for malignant melanoma.
MATERIALS AND METHODS
Materials
DOTAP and cholesterol were purchased from Avanti Polar Lipids
(Alabaster, AL). Protamine sulfate and calf thymus DNA were from
Sigma-Aldrich (St Louis, MO). Paclitaxel (Taxol) was purchased from
Bristol-Myers Squibb (New York, NY). Synthetic 19-nt RNAs with 30
dTdT overhangs on both sequences were purchased from Dharma-
con (Lafayette, CO). For quantitative studies, Cy-3 was conjugated to
a 50 sense sequence. 50-Cy-3-labeled siRNA sequence was also
obtained from Dharmacon. The sequence of the mouse c-Myc
siRNA was 50-GAACAUCAUCAUCCAGGAC-30. The sequence of the
human c-Myc siRNA was 50-AACGUUAGCUUCACCAACAUU-30
and the control siRNA with sequence 50-AATTCTCCGAACGTGT
CACGT-30 was obtained from Dharmacon. DSPE-PEG2000-anisa-
mide was synthesized in our laboratory using the methods described
earlier (Banerjee et al., 2004).
Cell culture
Murine melanoma B16F10 and human melanoma MDA-MB-435
(sigma receptor positive; Li et al., 2008b) cells were used in this
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incubation with 50 mM DSAA and DOTAP for 24 and 48 hours. DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DSAA, N,N-distearyl-N-methyl-N-2-
(N0-arginyl) aminoethyl ammonium chloride; ROS, reactive oxygen species.
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study. The cells were purchased from the American Type Culture
Collection. B16F10 cells were stably transduced with GL3 firefly
luciferase gene by using a retroviral vector produced in Pilar
Blancafort’s laboratory at the University of North Carolina at Chapel
Hill. The cells were maintained in DMEM (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen), 100Uml1
penicillin, and 100mgml1 streptomycin (Invitrogen).
Experimental animals
Female C57BL/6 mice 6–8 weeks of age were purchased from the
National Cancer Institute (Frederick, MD). All work performed on
animals was in accordance with and approved by the IACUC
committee at UNC.
Synthesis of DSAA
DSAA is a non-glycerol-based guanidine head group containing
cationic lipid synthesized in five steps. The synthesis is fairly simple.
N-alkylation by n-octadecyl bromide and subsequent Boc deprotec-
tion of mono-Boc-protected ethylene diamine yielded mixed
primary tertiary amine N1,N1-dioctadecylethane-1,2-diamine. Tri-
Boc-protected arginine conjugation to the primary amine group by
the conventional EDCI and quaternization of the tertiary amine
group using methyl iodide on the above obtained product gave
tri-Boc-protected DSAA. To obtain the final product DSAA, we
carried out (N-(2-(arginyl)ethyl)-N-methyl-N,N-dioctadecyl amo-
nium chloride) Boc group deprotection with TFA and chloride ion
exchange with Amberlyst A 27 (Cl) ion exchange resin. The
resulting compound was characterized by using 1H NMR spectra
and liquid secondary ion mass spectra. Detailed synthetic proce-
dures and spectral and purity data will be delineated elsewhere
(Bathula et al., unpublished data).
Analysis of ROS in B16F10 cells
B16F10 cells (1 106 per well) were seeded into 12-well plates.
Cells were incubated with 20mM 20,70-dichlorodihydrofluorescein
diacetate (Sigma-Aldrich) in serum-containing medium for 30min-
utes at 37 1C. Then, cells were treated with DSAA or DOTAP
liposomes at various doses in serum-containing medium at 37 1C for
1 hour. Cells were quickly washed and immediately analyzed by
flow cytometry.
Preparation of PEGylated LPD formulations
LPD were prepared according to the previously reported method
with slight modifications (Cui et al., 2005). Briefly, cationic
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Figure 7. Apoptosis induction and tumor growth inhibition of human melanoma by nanoparticles containing c-Myc siRNA and DSAA. (a) MDA-MB-435 cells
transfected with c-Myc or a control siRNA for 72 hours by lipofectamine 2000 and analyzed for Annexin V staining by flow cytometry. (b) Immunofluorescent
staining of c-Myc and TUNEL staining in the MDA-MB-435 xenograft tumors after three consecutive i.v. injections of RNAs in targeted nanoparticles DSAA
AAþ . Scale bar¼50 mm. (c) Quantitative analysis of TUNEL-positive staining in the tumors treated with different formulations (n¼ 3–6). (d) Comparison of
therapeutic efficacy of c-Myc (0.6mg kg1) and control siRNAs in the targeted nanoparticles DSAA AAþ . Arrows indicate the i.v. administrations of siRNA.
DSAA, N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammonium chloride; DSASS, N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammonium
chloride; SiRNA, small interfering RNA.
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liposomes composed of DOTAP or DSAA and cholesterol (1:1 molar
ratio) were prepared by thin film hydration followed by membrane
extrusion to reduce the particle size. To prepare LPD, we mixed
18 ml of protamine (2mgml1), 140ml of deionized water, and 24 ml
of a mixture of siRNA and calf thymus DNA (2mgml1) and kept it
at room temperature for 10minutes before adding 120ml of cationic
liposome (10mM). After 10minutes at room temperature, LPD was
mixed with 37.8ml of DSPE-PEG-AA or DSPE-PEG (10mgml1) and
incubated at 50–60 1C for 10minutes.
Cellular uptake study
B16F10 cells were seeded in 12-well plates (Corning, Corning, NY)
12 hours before experiments. Cells were treated with different
formulations at a concentration of 250 nM for 50-Cy-3-labeled siRNA
in serum-containing medium at 37 1C for 4 hours. Cells were washed
twice with phosphate-buffered saline, counterstained with
4,6-diamidino-2-phenyl indole, and imaged by using a Leica
(Bannockburn, IL) SP2 confocal microscope.
Western blot analysis
For in vivo study, B16F10 tumor-bearing mice (tumor size B1 cm2)
were injected with siRNA in different formulations through the tail
vein (1.2mg siRNA per kg) with one injection per day for
3 consecutive days. The day after the third injection, mice were
killed and tumor samples were collected. Extracted protein (40mg)
from the tumor was separated on a 10% acrylamide gel and
transferred to a polyvinylidene difluoride membrane. Membranes
were blocked for 1 hour in 5% skim milk and then incubated for
12 hours with polyclonal antibodies directed against c-Myc (Santa
Cruz Biotechnology) and actin (Santa Cruz Biotechnology) for
standardization. Membranes were washed in PBST (phosphate-
buffered saline, 0.1% Tween-20) and then incubated for 1 hour with
appropriate secondary antibodies. Membranes were again washed and
then developed by an enhanced chemiluminescence system according
to the manufacturer’s instructions (PerkinElmer, Covina, CA).
For in vitro Bcl-2 downregulation study, B16F10 cells were
seeded in 12-well plates (1 105 per well) for 24 hours. Cells were
treated with different lipids at the concentration of 50 mM and were
collected after 24 and 48 hours for measuring Bcl-2 expression by
western blot analysis as described above.
Tumor uptake study
Mice with tumors B1 cm2 in size were injected intravenously with
Cy-3-labeled siRNA (1.2mg kg1) and NBD-labeled cholesterol
(Avanti Polar Lipids) in different formulations. After 4 hours, mice
were killed and tissues were collected, fixed in 10% formalin, and
embedded in paraffin. Tumor tissues were sectioned (714 mm thick)
and imaged using a Leica SP2 confocal microscope.
Tissue distribution study
Mice with tumors B1 cm2 in size were injected intravenously with
NBD cholesterol in different formulations. After 4 hours, mice were
killed and tissues were collected and homogenized in lysis buffer
and incubated at room temperature for 30minutes. The supernatant
was collected after centrifugation at 14,000 r.p.m. for 10minutes
and 50ml supernatant was transferred to a black 96-well plate
(Corning). The fluorescence intensity of the sample was measured by
a plate reader (Bioscan, Washington, DC) at excitation wavelength
485 nm and emission wavelength 535 nm. Lipid concentration in
each sample was calculated from a standard curve.
TUNEL assay
TUNEL staining was performed as recommended by the manufac-
turer (Promega, Madison, WI). MDA-MB-435 tumor-bearing mice
were injected intravenously with siRNA formulated in the nanopar-
ticles. At 24 hours after the third injection, the mice were killed and
the tumors were collected for the TUNEL staining. Images from
TUNEL-stained tumor sections were captured with Leica SP2
confocal microscopy.
Tumor growth inhibition study
B16F10 tumor-bearing mice (size 16–25mm2) were injected
intravenously with different formulations containing siRNA
(1.2mg kg1) once per day for 3 days. Tumor size in the treated
mice was measured at different days after the treatment.
Analysis of serum cytokine levels
C57BL/6 mice were injected intravenously with siRNA against
c-Myc in formulations at the dose of 1.2mg siRNA per kg (1.2mg
DNA per kg for DSAA AAþ without siRNA). At 4 hours after the
injections, blood samples were collected from the tail artery and
allowed to stand on ice for 2 hours for coagulation. Serum was
obtained by centrifuging the clotted blood at 16,000 r.p.m. for
20minutes. Cytokine levels were determined by using ELISA kits for
IL-6 and IL-12 (BD Biosciences, San Diego, CA).
Liver enzyme assay
The C57BL/6 mice were injected intravenously with c-Myc siRNA
(1.2mg kg1) formulated in the targeted nanoparticles. At 24 hours
after injections, serum samples were obtained and the liver enzyme
(alanine aminotransferase, aspartate aminotransferase) levels were
analyzed by Animal Clinical Chemistry and Gene Expression
Laboratories, University of North Carolina.
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Figure 8. Schematic illustration of possible mechanisms of the combination
strategy using c-Myc siRNA and the cationic lipid DSAA. Cyt c, cytochrome c;
DSAA, N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammonium
chloride; siRNA, small interfering RNA.
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Statistical analysis
All statistical analyses were performed using Student’s t-test. Data were
considered statistically significant when the P-value was o0.05.
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